登录 | 注册    关注公众号  
微信公众号
搜索
 >  Cell>IL-23 R/IL-12 R beta 1 >CHEK-ATF166

Human IL-23 R/IL-12 R beta 1(Luc) HEK293 Reporter Cell

For research use only.

描述(Description)

The Human IL-23 R/IL-12 R beta 1 (Luc) HEK293 Reporter Cell was engineered to not only express STAT3 signaling response element, but also express the receptors full length human IL-23 R (Gene ID:149233) and IL-12 R beta 1 (Gene ID:3594). When stimulated with human IL-23 protein, receptor-mediated signaling can drive STAT3-mediated luminescence. Neutralization of biological effect of the ligand-receptor interaction by corresponding antibody results in a decrease in luminescence.

应用说明(Application)

•Screen for anti-human IL-23 neutralizing antibody.

IL-23 R/IL-12 R beta 1 Assay Principles

生长特性(Growth Properties)

Adherent

筛选标记(Selection Marker)

Puromycin (2 μg/mL) + Zeocin (20 μg/mL)

培养基(Culture Medium)

DMEM + 10% FBS

冻存液(Freeze Medium)

Serum-free cell cryopreservation medium

装量(Quantity)

1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

存储(Storage)

Frozen in liquid nitrogen.

支原体检测(Mycoplasma Testing)

Negative

无菌检测(Sterility Testing)

Negative

使用说明(Instructions for Use)

See data sheet for detailed culturing and assay protocol.

 

Receptor Assay

IL-23 R/IL-12 R beta 1 FACS

Co-expression analysis of human IL-23 R and IL-12 R beta 1 on Human IL-23 R/IL-12 R beta 1 (Luc) HEK293 Reporter Cell by FACS.
Cell surface staining was performed on Human IL-23 R/IL-12 R beta 1 (Luc) HEK293 Reporter Cell or negative control cell using PE-labeled anti-IL-23 R antibody and APC-labeled anti-IL-12 R beta 1 antibody.

Protocol

 

Application

IL-23 R/IL-12 R beta 1 APPLICATION

Inhibition of human IL-23 protein-induced reporter activity by anti-human IL-23 neutralizing antibody.
This reporter cell was incubated with serial dilutions of antibodies in the presence of human IL-23 protein (Cat. No. ILB-H52W5) with a final concentration of 0.1 μg/mL. The EC50 of Ustekinumab is approximately 0.08049 μg/mL, and the EC50 of Guselkumab is approximately 0.05874 μg/mL.

Protocol

 

Signaling Bioassay

IL-23 R/IL-12 R beta 1 SIGNALING

Response to human IL-23 protein (RLU).
The Human IL-23 R/IL-12 R beta 1 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human IL-23 protein (Cat. No. ILB-H52W5). The EC50 was approximately 0.3826 μg/mL.

Protocol

IL-23 R/IL-12 R beta 1 SIGNALING

Response to human IL-23 protein (FOLD).
The Human IL-23 R/IL-12 R beta 1 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human IL-23 protein (Cat. No. ILB-H52W5). The max induction fold was approximately 194.

Protocol

如有相关细胞池需求请联系我们

 

背景(Background)

IL-23 is a heterodimeric cytokine composed of p40 and p19 subunits. It binds to its IL-23 receptor complex composed of IL-12RB1 and IL-23R subunits, which are associated with the Jak family members, Tyk2 and Jak2, respectively. IL-23 binding to its receptor complex results in Jak2-mediated phosphorylation of tyrosine residues located in the intracellular domain of the IL-23R subunit. Phosphorylated tyrosine residues serve as a docking site for STAT3 molecules, which in turn get phosphorylated. Phospho-STAT3 proteins homodimerize and translocate into the nucleus inducing transcription of cytokines, such as IL-17A, IL-17F, IL-22 and IFN-.

 

Permits & Restrictions

This cell line is provided for research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. You are not allowed to share, distribute, sell, modify, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定